BioFocus, the Galapagos' service division, and Ono Pharmaceutical have signed a new drug discovery agreement focusing on CNS disorders.
BioFocus managing director and Galapagos Services SVP Dr. Chris Newton said, "This project plays to BioFocus historic strengths and the expanding breadth and depth of this partnership is testament to a tried and trusted relationship."
Pursuant to the agreement, whose financial details were kept confidential, BioFocus will leverage its drug discovery platform to deliver leads and clinical candidates.
Ono discovery and research executive officer and executive director, the Board member Kazuhito Kawabata said, "This collaboration will strengthen Ono's drug discovery capability in the field of CNS disorders with significant unmet medical needs and we are expecting that innovative drugs will be created through this collaboration."